Clinical Research Directory
Browse clinical research sites, groups, and studies.
The Effects of Mirabegron and Tadalafil on Glucose Tolerance in Prediabetics
Sponsor: Philip Kern
Summary
The investigator hypothesizes that treatment with the ß3 agonist mirabegron results in improved glucose metabolism, including a reversal of prediabetes in obese, insulin-resistant human research participants, and this is further improved by combination therapy with tadalafil. The investigator will comprehensively analyze glucose homeostasis in prediabetic patients treated for 14 weeks with mirabegron, tadalafil or both drugs as compared to a placebo.
Key Details
Gender
All
Age Range
35 Years - 65 Years
Study Type
INTERVENTIONAL
Enrollment
96
Start Date
2021-12-13
Completion Date
2026-08
Last Updated
2026-02-03
Healthy Volunteers
Yes
Conditions
Interventions
Mirabegron 50 MG
Mirabegron 50 mg/day will be administered for 14 weeks.
Tadalafil 10 MG
Tadalafil 10 mg/day will be administered for 14 weeks after baseline procedures.
Placebo
Placebo will be administered for 14 weeks after baseline procedures.
Locations (1)
University of Kentucky
Lexington, Kentucky, United States